CELLEGY WINS FIRST EUROPEAN APPROVAL FOR TOSTREX

Sweden's Medical Products Agency has given the green light to Cellegy's Tostrex testosterone gel. The gel, which uses a metered dose delivery system that can be adjusted for each individual patient, is used to treat male hypogondism. The condition often causes symptoms associated with the aging process, including reduced libido, muscle waste and reduced energy levels.

UK-based ProStrakan holds the rights to market Tostrex in Europe and will seek approval from other EU member states via the Mutual Recognition Procedure. A ProStrakan statement highlighted the company's belief that the European testosterone market has major growth potential.